Biotron Laboratories: 2014 HCS
750 N. 1250 W.
Centerville, UT 84014
Phone: (801) 298-8438
Fax: (801) 298-8800
Ferractiv: A Unique, Iron Multi-Amino Acid Chelate Ingredient
Perhaps the single most important factor for women considering supplementary iron is the frequent occurrence of uncomfortable side effects—such as stomach upset, bloating and nausea. Ferractiv iron supplement powder is unique, iron multi-amino acid chelate ingredient, which has been clinically proven to be well tolerated. A study of 60 healthy, premenopausal women in a randomized, double blind, placebo controlled trial showed a statistically significant reduction in side effects when given an equivalent amount of iron as Ferractiv, as compared to ferrous sulfate, one of the most commonly used and well absorbed iron salts.
Additionally, in-vitro experiments using a novel and highly sensitive iron absorption assay, developed by Dr. Ray Glahn and colleagues at the USDA (the U.S. Department of Agriculture) and the Cornell University Department of Food Science, have shown Ferractiv iron supplement to be highly bioavailable— meeting or exceeding the benchmark for bioavailability (ferrous sulfate—heptahydrate) in this model system.
This in-vitro work has been extended to the clinic, where large-scale (n=450) trials in pregnant, anemic women demonstrate the performance of Ferractiv iron supplement. Women receiving Ferractiv containing capsules responded more quickly, with fewer complaints of discomfort, when being treated for iron deficiency anemia by three separate clinical measurements. Importantly, these benefits were realized at a comparable cost on a per-dose basis when compared to frequently used alternatives.
Finally, Ferractiv has been studied at the atomic level in collaboration with the Canadian Light Source (CLS) at the University of Saskatchewan in Saskatoon, Canada. The CLS is Canada’s national synchrotron. This world–class research facility enables scientists and engineers to study the microstructure and chemical properties of materials. Ferractiv was analyzed using the Hard X-ray Micro Analysis Beamline 6ID. The collaboration between Biotron and the CLS has demonstrated a quantitative difference between both the bonding energy and bond distances of the atomic structures within the multiple amino acid matrix of Ferractiv. This data enables a definitive distinction to be made between this fully-reacted mineral chelate and other unreacted physical blends of irritating, low value inorganic salts.
Note: The work summarized here was published in the Journal of Dietary Supplements 10(1): 17-28, 2013. JDS is an Informa Healthcare publication.
1 Fouad, G.T., Evans, M., Barss, S., Baisly, J., Crowly, D. , Guthrie, N. “Safety and tolerability of iron amino acid chelate in premenopausal women.” Presented at FASEB, San Diego, California 2008.
2 Glahn, R.P., Lee, O.A., Yeung, A., Goldman, M.I., Miller, D.D. Caco-2 cell ferritin formation predicts nonradiolabeled food iron availability in an in-vitro digestion/Caco-2 cell culture model. J. Nutr. 1998 Sept; 128(9):1555-61.
3 Data on file. Biotron Laboratories, Inc. Centerville, Utah 84104 July, 2008.
4 Abdel-Lah. M., Rasheed, SI. Hassan, II. El-sayed. A. Iron chelated amino acid therapy versus oral iron therapy for the treatment of iron deficiency anemia with pregnancy. The Journal of the Egyptian Society of Obstetrics and Gynecology. 2006; Vol. 32 No. 4, 5 &6: 419-428.
5 Data on file. Biotron Laboratories, Inc. Centerville, Utah, 84104 (December, 2008). “X-Ray Absorption Spectroscope Measurements of Cr, Fe and Cu in Dietary Supplements.”